{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:39:16Z","timestamp":1760236756192,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Purpose: To estimate the frequency of first-time ocular events in patients treated with immune checkpoint inhibitors (ICI). Methods: Patients with cancer in 2011\u20132018 in Denmark were included and followed. The outcomes were first-time ophthalmologist consultation and ocular inflammation. One-year absolute risks of outcomes and hazard ratios were estimated. Results: 112,289 patients with cancer were included, and 2195 were treated with ICI. One year after the first ICI treatment, 6% of the patients with cancer, 5% and 8% of the lung cancer (LC) and malignant cutaneous melanoma (MM) patients, respectively, had a first-time ophthalmologist consultation. The risk of ocular inflammation was 1% (95% confidence interval (CI) 0.4\u20131.2). Among patients with MM, ICI was associated with ocular inflammation in women (HR 12.6 (95% CI 5.83\u201327.31) and men (4.87 (95% CI 1.79\u201313.29)). Comparing patients with and without ICI treatment, the risk of first-time ophthalmologist consultation was increased in patients with LC (HR 1.74 (95% CI 1.29\u20132.34) and MM (HR 3.21 (95% CI 2.31\u20134.44). Conclusions: The one-year risks of first-time ophthalmologist consultation and ocular inflammation were 6% and 1%, respectively, in patients treated with ICI. In patients with LC and MM, the risk was increased in patients with ICI compared with patients without ICI.<\/jats:p>","DOI":"10.3390\/cancers14010049","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:16:18Z","timestamp":1640254578000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer\u2014A Nationwide Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8784-9714","authenticated-orcid":false,"given":"Maria","family":"D\u2019Souza","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark"},{"name":"Department of Cardiology, Copenhagen University Hospital Herlev-Gentofte, 2900 Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Bagger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Alberti","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Malmborg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev-Gentofte, 2900 Gentofte, Denmark"},{"name":"The Danish Heart Foundation, 1127 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev-Gentofte, 2900 Gentofte, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Public Health, Copenhagen University, 1353 Copenhagen, Denmark"},{"name":"Department of Cardiology, Copenhagen University Hospital Hiller\u00f8d, 2400 Copenhagen, Denmark"},{"name":"Department of Cardiology, Aalborg University Hospital, 9100 Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev-Gentofte, 2900 Gentofte, Denmark"},{"name":"The Danish Heart Foundation, 1127 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"},{"name":"Department of Oncology, Copenhagen University Hospital Herlev-Gentofte, 2730 Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-1460","authenticated-orcid":false,"given":"Jens Folke","family":"Kiilgaard","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential Binding Properties of B7-H1 and B7-DC to Programmed Death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Huehn, M., Gaebel, J., Oeser, A., Dietz, A., Neumuth, T., Wichmann, G., and Stoehr, M. (2021). Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent\/Metastatic (R\/M) Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers, 13.","DOI":"10.3390\/cancers13235890"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., and Cheli, Y. (2021). Immune Checkpoints in Cancers: From Signaling to the Clinic. Cancers, 13.","DOI":"10.3390\/cancers13184573"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"BSR20192347","DOI":"10.1042\/BSR20192347","article-title":"Treatment- and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Advanced Lung Cancer","volume":"40","author":"Shao","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities Associated with Checkpoint Inhibitors\u2014An Overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"JCO"},{"key":"ref_15","unstructured":"Parikh, R.A., Chaon, B.C., and Berkenstock, M.K. (2020). Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series. Ocul. Immunol. Inflamm., 1\u20136."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular Adverse Events Following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"701951","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors Associated with Ocular Adverse Event after Immune Checkpoint Inhibitor Treatment","volume":"69","author":"Kim","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ije\/dyx108","article-title":"Data Resource Profile: The Danish National Prescription Registry","volume":"46","author":"Schmidt","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: A Review of Content, Data Quality, and Research Potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin. Epidemiol."},{"key":"ref_21","first-page":"441","article-title":"The Danish Civil Registration System","volume":"53","author":"Pedersen","year":"2006","journal-title":"Dan. Med. Bull."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish Register of Causes of Death","volume":"39","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"ref_23","unstructured":"Broe, M., Mattson, T., Bj\u00f8dstrup, P., and Potteg\u00e5rd, A. (2019). Validity of Chemotherapy Procedure Codes in the Danish National Patient Registry. Abstract Book, Danske Kr\u00e6ftforskningsdage."},{"key":"ref_24","unstructured":"R Core Team (2020). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-Related Ocular Toxicities in Solid Tumor Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review","volume":"17","author":"Oweira","year":"2017","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bomze, D., Meirson, T., Hasan Ali, O., Goldman, A., Flatz, L., and Habot-Wilner, Z. (2020). Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul. Immunol. Inflamm., 1\u20137.","DOI":"10.1080\/09273948.2020.1773867"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1\/PD-L1 Anticancer Immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular Adverse Events with Immune Checkpoint Inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint Inhibitor Immune Therapy Systemic Indications and Ophthalmic Side Effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/WNO.0000000000001148","article-title":"Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1\/PD-L1 Checkpoint Blockade","volume":"41","author":"Sun","year":"2021","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/ICB.0000000000000675","article-title":"Immune Retinopathy Associated with Nivolumab Administration for Metastatic Non-Small Cell Lung Cancer","volume":"14","author":"Reddy","year":"2020","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","article-title":"Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series","volume":"126","author":"Kim","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic Adverse Effects of Immune Checkpoint Inhibitors: The Mayo Clinic Experience","volume":"105","author":"Fortes","year":"2020","journal-title":"Br. J. Ophthalmol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:51:48Z","timestamp":1760169108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14010049"],"URL":"https:\/\/doi.org\/10.3390\/cancers14010049","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}